Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)

NCT00130923 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.

NCT NCT00130923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)
Lead sponsor
Dartmouth-Hitchcock Medical Center
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2005
Completion date
July 31, 2010
Enrollment
95 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol abuse, psychotic disorders, schizophrenia, substance abuse